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Accepted 8 December 2020; Published online 15 December 2020AbstractObjectives: Control conditions’ influence on effect estimates of active psychotherapeutic interventions for depression has not been
fully elucidated. We used network meta-analysis to estimate the differences between control conditions.
Study Design and Setting: We have conducted a comprehensive literature search of randomized trials of psychotherapies for adults
with depression up to January 1, 2019 in four major databases (PubMed, PsycINFO, Embase, and Cochrane). The network meta-
analysis included broadly conceived cognitive behavior therapies in comparison with the following control conditions: Waiting List
(WL), No Treatment (NT), Pill Placebo (PillPlacebo), Psychological Placebo (PsycholPlacebo).
Results: 123 studies with 12,596 participants were included. The I-squared was 55.9% (95% CI: 45.9%; to 64.0%) (moderate hetero-
geneity). The design-by-treatment global test of inconsistency was not significant (P 5 0.44). Different control conditions led to different
estimates of efficacy for the same intervention. WL appears to be the weakest control (odds ratio of response against NT 5 1.93 (1.30 to
2.86), PsycholPlacebo 5 2.03 (1.21 to 3.39), and PillPlacebo 5 2.66 (1.45 to 4.89), respectively).
Conclusions: Different control conditions produce different effect estimates in psychotherapy randomized controlled trials for depres-
sion. WL was the weakest, followed by NT, PsycholPlacebo, and PillPlacebo in this order. When conducting meta-analyses of psychother-
apy trials, different control conditions should not be lumped into a single group.  2020 Elsevier Inc. All rights reserved.
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60 I. Michopoulos et al. / Journal of Clinical Epidemiology 132 (2021) 59e701. Introduction comparisons of interventions A and B is combined with in-More than 300 million people are affected by depression
globally [1]. Its prevalence has substantially increased for
the last 30 years, due to population growth and aging [2].
In high-income countries, it is estimated that depression will
be the main cause of disability by the year 2030 [1]. Depres-
sion is a publicehealth priority [3e5]. Psychotherapy is one
of the two major interventions for depression [6,7]. There is
accumulating evidence that psychotherapeutic interventions
can contribute a lot or even be the major therapeutic
approach for several mental disorders [8,9]. Several psycho-
logical interventions have been developed and have shown
efficacy for the treatment of depression [10].
Such recommendations are based on randomized evidence.
A randomized controlled trial (RCT) is a planned experiment
designed to test the efficacy or effectiveness of an intervention
[11]. Use of control conditions is the primary methodology to
reduce threats to internal validity in RCTs. The purpose of a
control condition is to filter out the variance due to factors that
are not specific to the experimental intervention, leaving only
the variance due specifically to this treatment [12,13]. Awell-
designed control condition should maximize our confidence
that any difference in the results between the intervention
and the control is due to the specific effect of the intervention
and not to other general nonspecific factors [14]. The ideal
would be to control for: the regression toward the mean, the
natural course of the disease, the Hawthorne effect (due to be-
ing observed and evaluated, growing the sense of being under
medical attention and subsequently growing hope), and the
placebo effect (due to belief of being treated, including expec-
tation). In pharmacological studies, the pill placebo is used as
a control condition and can control for all above factors. How-
ever, the trial design for behavioral interventions has some
unique characteristics and control groups vary widely, which
influence the effects observed in any given trial. The effects
shown for the psychotherapeutic intervention depend on the
control condition, and there is indirect evidence suggesting
that different control conditions produce different effect sizes
[12,13,15]. Depression and anxiety disorders show large pla-
cebo responses in comparison with schizophrenia and bipolar
disorder [16]. Hope, attention and expectations for improve-
ment play an important role in the treatment of depression
[15,17,18]. The control condition could trigger improvement,
no response, or even produce a nocebo effect [19]. It is also
shown repeatedly that all bona fide psychotherapies, even
when used as control conditions, show similar effectiveness
[20,21]. On the other hand, many meta-analyses have paid lit-
tle attention to control conditions in psychotherapeutic trials
and may have lumped together various inactive conditions
into one comparison [12,22]. However, it is of utmost impor-
tance to examine the possible differences among the various
inactive control conditions empirically.
Network meta-analysis (NMA) is a recently developed
method of evidence synthesis. In network meta-analyses,
the information available from within-trial directdirect comparisons of A and B derived from trials that
compare either of the two interventions with a common
comparator C (either a third psychological intervention or
a control condition), thus enabling more precise estimates
of the relative efficacy among alternative interventions
(including alternative control conditions) while preserving
randomization [23]. NMA permits the comparison of more
than two interventions simultaneously (in contrast to pair-
wise meta-analyses). The synthesis of direct and indirect ev-
idence makes it feasible to compare interventions that would
never (or seldom) be compared withy each other in RCTs
(such as control conditions). In this way, NMA appears as
the best method to accurately estimate the different effi-
cacies of different interventions, as long as transitivity and
similarity between these interventions are fulfilled. Estab-
lishing which control condition may underestimate or over-
estimate the effect of psychological interventions through
NMA by including several control conditions in the same
network simultaneously may touch the very foundation of
research into psychological interventions, and may change
our interpretation of their empirical evidence base [24,25].
The objective of this study is to examine the influence of
the control conditions on effect estimates in psychotherapy
trials for depression through NMA. Our hypothesis is that
the choice of control condition has an impact on the effect
size estimates in RCTs for psychotherapy in depression.2. Methods
The protocol for this systematic review has been prereg-
istered on the Open Science Foundation platform as part of
the overall meta-analysis project (http://www.osf.io/cdfu2).
We followed Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) reporting guideline
for NMA [26].
2.1. Criteria for considering studies for this review
2.1.1. Types of participants
2.1.1.1. Inclusion criteria. Participants aged 18 years or
older, of both sexes, with a depressive disorder or with
elevated levels of depressive symptoms, diagnosed as per
operationalized criteria (DSM-III, DSM-III-R, DSM-IV,
DSM-IV-TR, DSM-5, or ICD-10) or judged so based on a
scale used for screening. All studies in which 80% or more
of the participants were deemed to satisfy the above criteria
were included.
2.1.1.2. Exclusion criteria. We excluded studies recruiting
children and adolescents. We also excluded patients who
suffer from bipolar depression or psychotic depression.
2.1.2. Types of studies
2.1.2.1. Inclusion criteria. Only RCTs comparing a
broadly conceived cognitive behavioral intervention head-
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behavioral intervention were included. The psychological
intervention had to be implemented at the individual,
group, or family level, include face-to-face contact between
the patient and the therapist (as opposed to telephone or
internet-based interaction between patient and therapist)
and consist mainly of verbal communication. Therapies
should last at least 4 weeks, but less than 6 months, because
this is the threshold for the acute phase. We included trials
reported as full-text articles in international peer-reviewed
journals and did not include studies reported as abstract on-
ly or as dissertation only. No language restrictions and re-
strictions on publication type were applied.
2.1.2.2. Exclusion criteria. Quasi-RCTs, in which treat-
ment assignment is decided through methods such as alter-
nate days of the week, were excluded. Medical or
psychiatric comorbidity was not an exclusion criterion.
Studies in which a pharmacological coadministration
was allowed were included, so long as it was administered
equally across the arms. The influence of including trials al-
lowing coadministration of drugs was examined in a sensi-
tivity analysis.2.1.3. Types of interventions
2.1.3.1. Control conditions. Table 1 provides the detailed
definitions of the four control conditions of interest for this
review.
Care as usual (CAU. Sometimes referred as treatment as
usual) is a frequently used control condition in psychother-
apy trials. However, the actual contents of CAU differ
across settings and across studies [27e29]. Sometimes,
no other treatment is available, so patients in the control
group receive no treatment at all. Sometimes, a general
practitioner gives treatment for depression. Some other
times, a qualified psychiatrist is responsible for the treat-
ment and may give antidepressants or/and psychotherapy.
In some cases, CAU can be described as ‘‘psychotherapeu-
tic’’ or ‘‘nonpsychotherapeutic’’ [30]. Such varieties cannot
be studied as one node in the network in our present study
of control conditions in psychotherapy trials.
We therefore classified what was described as ‘‘treat-
ment as usual’’ or ‘‘care as usual’’ in the original publica-
tion by its contents, where appropriate, as Waiting List
(WL,) PsycholPlacebo, or NoTreatment (NT) as per the
following rules.
1) If the control condition is used as a waiting list, it is
classified as WL.
2) If the trial is CBT þ CAU vs. CAU, and this CAU is
for depression (e.g., 20% or more patients received
antidepressants and/or psychotherapy), we excluded
such a trial because it would not contribute to a com-
parison of CBT against NT or PsycholPlacebo.
3) If the trial is CBT þ CAU vs. CAU but this CAU is
not for depression (but e.g., for diabetes orhypertension or when this proportion was less than
20% or when it was only information provision),
we considered this trial as comparing CBT vs. NT.
We conducted a sensitivity analysis to examine the
robustness of including such trials.
4) If the trial is CBT vs CAU, we classified this CAU as
per its content as NT or PsycholPlacebo.
2.1.3.2. Active interventions. Studies with an active drug as
active intervention were not eligible. Clinical heterogeneity
within therapeutic approaches is an issue that often arises
in psychotherapeutic studies [10]. To reduce this problem,
we focused on broadly conceived cognitive or behavioral
psychotherapies, as proposed by an expert taxonomy of psy-
chotherapy for depression [10,14,31], including cognitive
behavioral therapy (CBT), behavioral activation (BA),
problem-solving therapy, and 3rd wave CBT (3W).
Table 1 provides the definitions for respective interventions.
2.1.4. Types of outcomes
The primary outcome was the response, defined as 50%
or greater reduction in depressive symptomatology from
baseline to the end of the study. The secondary outcome
was the depression severity at end of treatment. When only
change scores were provided, we pooled them with end
point scores [32]. The outcome was assessed at the end
of the acute phase treatment for every study. If more than
one assessment times were reported, we extracted the last
assessment immediately after the acute phase intervention
(between 4 weeks and 6 months). Follow-up was not
included. For each comparison, the effect size indicating
the difference between the two arms was expressed as the
odds ratio (OR) [33] or as standardized mean difference
corrected for small sample size [34]. We included only vali-
dated depression measures. However, when more than one
measure was used in a study, we prioritized the scales in the
following order to minimize potential selective outcome re-
porting bias: 1) Hamilton Rating Scale for Depression (any
version), 2) Beck Depression Inventory I or II, 3) another
clinician-rated instrument, or 4) another self-report
instrument.
2.2. Data collection
2.2.1. Search methods for identification of studies
We based the present study on the database of random-
ized trials of psychotherapies for depression [35]. This
database has been continuously updated by a comprehen-
sive literature search up to January 1, 2019 of four major
bibliographical databases (PubMed, PsycINFO, Embase,
and the Cochrane Library). The search used a combination
of index and text terms indicative of depression and psy-
chotherapies, with filters for RCTs. Appendix A gives the
full search string for one database (PubMed). Furthermore,
we checked the references of earlier meta-analyses on psy-
chological treatments of depression.
Table 1. Definitions of control conditions and cognitive behavioral interventions included in this review
Controls and interventions Description/definition
No psychological treatment (NoTreatment) Participants receive assessment only, with or without simple provision of informational
material and/or minimal therapist contact, and they know that they will not receive
the active treatment in question after the trial.
Waiting list (WL) Participants receive assessment, with or without simple provision of informational
material and/or minimal therapist contact, and they know that they will receive the
active treatment in question after the waiting phase.
Psychological placebo (PsycholPla) Participants receive a face-to-face inactive intervention that can be perceived effective
by the participants. They spend time with the therapist of the same duration and
frequency with the experimental treatment, but no specific therapeutic techniques
are administered. Supportive counseling will be included under this category if it is
intended to serve as a control condition as defined previously in the design of the
study.
Pill placebo (PillPla) Participants receive an inactive pill. This usually happens when a multiarm trial is
conducted.
Cognitive behavioral therapy (CBT) In CBT, the therapists focus on the impact that a patient’s present dysfunctional
thoughts have on current behavior and future functioning. CBT is aimed at
evaluating, challenging, and modifying a patient’s dysfunctional beliefs (cognitive
restructuring). In this form of treatment, the therapist mostly emphasizes homework
assignments and outside-of-session activities. Therapists exert an active influence
over therapeutic interactions and topics of discussion, use a psycho educational
approach, and teach patients new ways of coping with stressful situations. The most
used subtypes are CBT according to Beck’s manual (Beck et al., 1979) and the
‘‘Coping with Depression’’ course (Lewinsohn et al., 1984).
Behavioral activation therapy (BA) We considered an intervention to be behavioral activation when the registration of
pleasant activities and the increase of positive interactions between a person and his
or her environment were the core elements of the treatment. Social skills training
could be a part of the intervention. There are several subtypes of behavioral activation
(Mazzucchelli et al. 2009).
Problem solving therapy (PST) We defined PST as a psychological intervention in which the following elements had to
be included: definition of personal problems, generation of multiple solutions to each
problem, selection of the best solution, the working out of a systematic plan for this
solution, and evaluation as to whether the solution has resolved the problem.
Subtypes of PST are described elsewhere (Cuijpers et al., 2018).
Third wave cognitive behavioral therapies (3W) Third wave therapies are a heterogeneous group of therapies that introduce several new
techniques to cognitive behavior therapies. They have in common that they abandon
or only cautiously use content-oriented cognitive interventions and the use of skills
deficit models to delineate the core maintaining mechanisms of the addressed
disorders (Kahl, Winter, & Schweiger, 2012). Well-known therapies that we clustered
in this category include acceptance and commitment therapy, mindfulness-based
CBT, and metacognitive therapy.
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Two independent review authors (EK, PC, MC, and CM)
examined the abstracts of all publications obtained through
the search strategy. Full articles of all studies identified by
at least one of the two review authors were then obtained
and inspected by the same review authors. Conflicts of
opinion regarding eligibility of a study were discussed, hav-
ing retrieved the full article and consulted the authors if
necessary, until consensus was reached. Methodological ex-
perts (TAF and PC) were consulted if necessary.2.2.3. Data extraction and management
Data from each study were extracted by two independent
review authors (IM, SK, AO, and EGO). Any disagreement
was resolved through discussion and in consultation withthe principal investigators. Where necessary, the authors
of the studies were contacted for further information.2.2.4. Assessment of risk of bias in included studies
Two independent review authors (EK, PC, MC, and CM)
assessed the risk of bias in selected studies. Any disagree-
ment was resolved through discussion and in consultation
with the principal investigators (PC and TAF).
Risk of bias was assessed for each included study using
the Cochrane Collaboration risk of bias tool as a model
[36]. The following domains were considered: adequate
generation of random sequence, allocation concealment,
blinding of outcome assessors, and dealing with incomplete
outcome data. A study was rated as low overall risk of bias
when all four items were rated as low risk, as moderate
63I. Michopoulos et al. / Journal of Clinical Epidemiology 132 (2021) 59e70overall risk of bias when three or two items were rated at
low risk, and as high overall risk of bias when only one
or no item was rated at low risk.
2.2.5. Dealing with missing data
When the response rate was not reported, we imputed it
using the mean at baseline and the mean and SD at end
point [37]. Patients randomized but not included in the orig-
inal analyses were assumed to be nonresponders and
included in the current analyses following the intention-
to-treat principle. Missing continuous outcome data were
analyzed on an end point basis, by using the last observa-
tion carried forward (LOCF) to the final assessment if
LOCF data were reported by the trial authors or by
including only participants with a final assessment. When
P-values, t-values, confidence intervals, or standard errors
were reported in articles, SD was calculated from their
values.
2.3. Data synthesis
We conducted NMA to synthesize the available evidence
from the entire network of trials by integrating direct and
indirect estimates for each comparison into a single sum-
mary treatment effect. We used the package netmeta
(version 1.2-0) of R (version 3.6.1) for all analyses, except
for gemtc (version 0.8-2) and JAGS (version 4.3.0) for
metaregression analyses to investigate sources of heteroge-
neity and OpenBUGS (version 3.2.3) for metaregression
analyses adjusting for small study effects between interven-
tions and control conditions [38].
2.3.1. Assessment of statistical heterogeneity
We assessed statistically the presence of heterogeneity
using the I-squared statistic and its 95% confidence interval
that measures the percentage of variability that cannot be
attributed to random error. The degree of statistical hetero-
geneity in the entire network was assessed through the
magnitude of the heterogeneity variance parameter (t2)
estimated from the NMA models. t2 was compared with
the empirical distribution as derived for dichotomous and
continuous outcomes [39,40].
2.3.2. Assessment of transitivity and statistical
inconsistency
Transitivity is the basic prerequirement of NMA: it re-
quires that potentially important effect modifiers are evenly
distributed among the comparisons. We assessed transi-
tivity by examining the average age, proportion of women,
recruitment settings, use of operational diagnostic criteria,
and number of sessions among comparisons which had five
or more included studies.
Consistency in the network (i.e., direct and indirect evi-
dence are in agreement) is statistical expression of transi-
tivity: it can be violated either in the entire network or in
certain parts (i.e., loops of evidence) of the network. Weevaluated the presence of inconsistency using the following
approaches:
2.3.2.1. Global tests. To check the assumption of consis-
tency in the entire network simultaneously we used the
‘‘design-by-treatment’’ model [41]. This method accounts
for different sources of inconsistency that can occur when
studies with different designs (two-arm trials vs. three-
arm trials) give different results as well as disagreement be-
tween direct and indirect evidence. Using this approach, we
inferred about the presence of inconsistency from any
source in the entire network based on a chi-square test.
2.3.2.2. Local tests. To evaluate the presence of inconsis-
tency locally, we used the side-splitting approach [42]. This
method evaluates the consistency assumption by statisti-
cally comparing the direct estimate and the indirect esti-
mate for each mixed estimate.
2.3.3. Investigation of sources of heterogeneity and
inconsistency
We explored possible sources of heterogeneity and
inconsistency [43] through metaregression using the poten-
tial effect modifiers listed below.
1. Year of publication
2. Blinding of outcome assessors2.3.4. Investigation of small study effects
Small study effects including publication bias may be
expected between active treatments and controls. We exam-
ined this by drawing funnel plots between all control con-
ditions and all active interventions.
2.3.5. Sensitivity analyses
We conducted the following three sensitivity analyses.
1. Treating all active psychotherapies as one node in the
network, given little evidence for differences in effi-
cacy among active psychotherapies [10,14].
2. Excluding studies which examined psychotherapies
among patients with physical comorbidities because
in such trials face-to-face interventions targeting
physical comorbidities were administered to both
active arms and control arms and may have dampened
the possible differences between them.
3. Excluding studies at high risk of bias.
4. If small study effects were observed, adjusting for
study variance for comparisons with suspected small
study effects.2.4. Changes from the protocol
The primary outcome was changed from the continuous
outcome of depression severity to the dichotomous
outcome of response in depression. The dichotomous
64 I. Michopoulos et al. / Journal of Clinical Epidemiology 132 (2021) 59e70outcome was preferred because it enables closer adherence
to the intention-to-treat principle by conservatively
assuming all dropouts to be no-responders and also because
the obtained results are more clinically interpretable [44].
The analyses for the continuous outcome, however, were
reported as the secondary outcome.
In the primary network, we differentiated different forms
of cognitive and/or behavioral therapies. This was per-
formed to increase the connectedness of the network, so
that the mixed estimates would be more stable and more
consistent. However, a NMA lumping all broadly
conceived CBT interventions into one node was reported
as a sensitivity analysis.
The prespecified sensitivity analysis to exclude studies
which had allowed coadministration of drugs could not
be conducted as most of the study reports were not clear
if they had allowed such and if the patients in fact received
such during the original randomized trials. We added one
sensitivity analysis excluding studies at high risk of bias,
as requested by one of the reviewers.3. Results
3.1. Included studies
After examining 22,049 abstracts (16,701 after removal
of duplicates), we assessed 2,553 full-text articles for eligi-
bility, in which we identified 308 RCTs of psychotherapies
comparing one against another or against a control condi-
tion. By limiting the psychotherapies to broadly defined
cognitive behavioral ones and by scrutinizing the contents
of the control conditions, we finally arrived at 123 studies
(12,596 participants) for inclusion in the current NMA.
Appendix B depicts the PRISMA flowchart, Appendix C
presents the references, and Appendix D presents the
selected characteristics of the included studies. Appendix
D also provides detailed descriptions of interventions
judged to constitute PsycholPlacebo and NoTreatment,
with citations from the original publications to support
our judgments.
3.2. Characteristics of the included studies and
participants
Table 2 presents the aggregated characteristics of the
included studies and the participants. The 123 included
studies were published between 1977 and 2018 (median:
2009). The participants were in their 40s on average, and
69% were women. Approximately, half were diagnosed
with major or minor depression, whereas the others were
selected based on a cutoff score of a rating scale.
Appendix D provides the risk of bias assessments for in-
dividual studies. Overall, 31 studies (25.2%) were consid-
ered to be at low overall risk of bias, 49 (39.8%) at
moderate risk, and 43 (35.0%) at high risk of bias.3.3. Network meta-analyses
Figure 1 presents the network diagram of the included
studies for the primary outcome. Among the control condi-
tions of interest, there was only one direct comparison be-
tween WL and PsycholPlacebo. However, overall, the
network was well connected, without any singly standing
node, and every control condition was compared at least
with three active intervention nodes.
Table 3 shows the league table among all psychother-
apies and control conditions for response (lower left trian-
gle) and depression severity (upper right triangle). Figure 2
shows the ranked forest plot, with WL as a reference. There
were no statistically significant differences among the
active interventions, which were all significantly superior
to all control conditions (except for 3W over PillPlacebo).
Among the control conditions, PillPlacebo, NoTreatment,
and PsycholPlacebo were all significantly superior to WL.
The effect sizes of psychotherapies, therefore, were sub-
stantively different depending on which control condition
was used.
3.4. Investigation of heterogeneity and inconsistency
I-squared of the network was 55.9% (95% CI: 45.9%; to
64.0%) and suggested moderate heterogeneity. Tau-
squared, the common heterogeneity parameter, was 0.35,
well within the 95% prediction interval for tau-squared
(0.005e3.33) for subjective outcomes in nonpharmacolog-
ical interventions [45].
Potential effect modifiers were apparently evenly distrib-
uted across comparisons, especially when there were more
than 10 studies included per comparison, suggesting that
the transitivity of the network was maintained. The
design-by-treatment global test of inconsistency was not
significant (P 5 0.44). None of the side-splitting tests sug-
gested inconsistency between direct and indirect estimates
beyond chance (Appendix E).
The funnel plot of comparisons between active psycho-
therapies and various control conditions was highly asym-
metric (Appendix F, Egger’s P ! 0.001).
None of the meta-regressions by year of the study or
blinding of assessor was statistically significant, with esti-
mated coefficients of 0.42 (1.22 to 0.37) and 0.86
(0.01 to 1.75), respectively.
3.5. Sensitivity analyses
We first attempted a prespecified sensitivity analysis
lumping all broadly conceived CBT arms into one node.
However, the network (Appendix G) turned out to be
disconnected, and we deemed it not worthwhile to run
NMA on this network.
Appendix H shows the results of the other three sensi-
tivity analyses. When we excluded studies targeting pa-
tients with comorbid physical diseases or studies with
Table 2. Aggregate characteristics of the included studies
N % Mean SD or range
Participants
Mean age 45.4 (Range: 18.2-81.9)






Adults in general 46 37.4%
Older adults 15 12.2%
Students 12 9.8%
Perinatal depression 7 5.7%
General medical disorder 30 24.4%
Other 13 10.6%
Diagnosis
Major depression 38 30.9%
Major and minor depression 27 21.9%
Cutoff score 51 41.5%
Subclinical depression 6 4.9%
Chronic depression 1 0.8%
Interventions
























Year of the study 2006 (Median 2009; Range: 1977-2018)
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Table 2. Continued




East Asia 9 7.3%
Other 14 11.4%
Risk of bias (low)
Sequence generation 56 45.5%
Allocation concealment 50 40.6%
Blinding of assessor 41 33.3%
ITT analysis 65 52.8%
a The denominator is the total number of arms (not the total number of studies).
66 I. Michopoulos et al. / Journal of Clinical Epidemiology 132 (2021) 59e70high risk of bias, the results were essentially similar to the
primary results. When we adjusted for small study effects
between active interventions and control conditions through
metaregression, the effect sizes became much smaller and
only BA, CBT, and 3W were significantly more effective
than WL: however, the ranking of the interventions and
the control conditions remained the same.4. Discussion
4.1. Principal findings
In this NMA, we assessed comparative data from 123
randomized trials of psychotherapies in the acute phase of
depression. The network was well connected, homogenous,
and consistent. Broadly conceived CBT therapies were
used as active interventions. We found that there are impor-
tant differences among the various control conditions typi-


























Fig. 1. Network diagram for response.conditions lead to different estimates of efficacy for the
same intervention. Among them, WL appears to be the
weakest, that is, an active intervention will have the biggest
effect size when the control condition is WL. By contrast,
PillPlacebo appears to be the strongest control condition,
with PsycholPlacebo and NoTreatment coming inbetween.4.2. Strengths and limitations of the study
To our knowledge, it is the first NMA comparing all
typical control conditions including WL, NoTreatment,
PsycholPlacebo, and PillPlacebo simultaneously in the
NMA. The identified studies fulfilled two basic assump-
tions for NMA: it had moderate heterogeneity
(I2 5 55.9%) and there was no evidence for inconsistency
in the network. Using the rigorous definitions for control
conditions, we were still able to include 123 studies
(12,596 participants) in the network, enabling more precise
estimates for relative efficacies among various control
conditions.
Furthermore, we have included studies that are not
limited to western countries, but from all continents, from
different health systems and different cultures; this makes
our findings more comprehensive. We did not include the
term ‘‘CAU’’ (‘‘Care as usual’’ or ‘‘Treatment as usual’’)
as its contents vary enormously, and it produces great het-
erogeneity [27,29]. CAU can range from an intervention
with antidepressants plus psychotherapy to no intervention
at all, depending on the settings and available resources
[46]. In an effort to reduce the heterogeneity of CAU,
Wampold et al. (2011) suggested the use of a scale to clas-
sify CAU as ‘‘psychotherapeutic’’ or not [30]. We classified
CAU as per the actual treatments given to patients, which
reduced heterogeneity and allowed us to focus on compar-
isons among rigorously defined control conditions.
Compared with psychopharmacological trials, psycho-
therapeutic trials appear with higher risk of bias because
there is no way for a psychotherapeutic trial to be double


















































































































In the lower left triangle, ORO1 means that the column-defining intervention increases the response in comparison with the row-defining inter-
vention. In the upper right triangle, SMD!0 means that the row-defining intervention decreases the depression severity more than the column-
defining intervention.
Bold indicates statistically significant effect sizes.
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included, lowering the risk of bias; about two-thirds of
the studies had low to moderate risk of bias. We included
only face to face interventions: in this way, the placebo ef-
fect was homogeneous for all the comparisons examined.
We excluded the studies that had more than 20% coadmin-
istration with drugs, which diminished confounding by the
presence of antidepressants.
Another important issue is publication bias, whereby the
‘‘negative’’ results are less likely to be published. Unfortu-
nately, there is no established method to adjust for such
small study effects. We found significant asymmetry in
the funnel plot of comparisons between active psychother-
apies vs. control conditions (Appendix F). If the small
study effects existed to the same degree only between
active interventions, on the one hand, and control condi-
tions, on the other, the comparative effectiveness among
the first group and among the second group, respectively,
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Fig. 2. Ranked forest plots for response in the primary analysis.for variance in the comparisons between active interven-
tions and controls expectedly reduced the effect sizes of
the former over the latter and also among the former or
the latter arms themselves. However, the relative rankings
remained the same.
Last but not least, this NMA is not exempt from the lim-
itations of the original studies in it: for example, the partic-
ipants were those who had consented to randomized research
and may not be representative of those who would seek psy-
chotherapies; the interventions and their therapists may be
better controlled and of higher quality than those actually
administered in the real world; the therapists and their super-
visors were not randomized within trials and there may be
confounding between interventions and therapists.
4.3. Comparison with other studies
The role of control conditions in psychotherapeutic trials
has been investigated before. Mohr et al. found differences
among control conditions and suggested that the choice of
the control condition has an impact on the effect sizes
found between the active treatment and the control condi-
tion [12]. However, great heterogeneity was present, and
they did not use a NMA, but they performed multiple
meta-analyses, making the synthesis of the results uncer-
tain. They had included CAU as a control condition,
without distinguishing its elements and found that CAU
produced similar effect sizes to WL and NT. Considering
WL vs. NT, they found that WL presented greater effect
sizes for active psychotherapies than NT, something that
is in line with our findings.
Furukawa et al. applied a NMA including CBT as the
active intervention and WL, NT, and PsycholPlacebo as
68 I. Michopoulos et al. / Journal of Clinical Epidemiology 132 (2021) 59e70control conditions [19]. They had also excluded CAU, to
reduce heterogeneity, but they had not included pill pla-
cebo, which appears in our analysis as a strong control con-
dition. They reported WL as a ‘‘nocebo condition’’ because
it produced bigger effect sizes than PsycholPlacebo and
even NT. The present study has more than doubled the sam-
ple size and has been able to lead to firmer inferences about
relative efficacies among various control conditions.
Barth et al. performed a NMA comparing the efficacy of
psychotherapeutic interventions for depression [14]. Apart
from their main findings, they also concluded that different
control conditions produce different effect sizes. They used
CAU as a control condition, although they reported that
CAU is a factor that can confound the results. They also
lumped psychological placebo and pill placebo as one con-
trol condition, whereas in our study, the latter appeared
stronger than the former.
Munder et al. [21] were based on data from Cuijpers et al.
[47] and tried to distinguish the efficacy of different psycho-
therapeutic approaches for depression. Following Cuijpers
et al. methodology, they included CAU and ‘‘other’’ controls
in their analyses. They also performed multiple separate an-
alyses and excluded outliers, ‘‘based on visual inspection.’’
Apart from their main outcomes, they examined control con-
ditions as well. But they did not test the differences of con-
trol conditions among each other. They also considered WL
as the same with NT, whereas in our study, these two condi-
tions differ (in theory and in ‘‘effectiveness’’). They
concluded that WL is not a ‘‘nocebo’’ control condition
but it could reflect the natural course of depression.
Depression is a disorder with a large placebo response
[16,17]. Being under medical attention, even if this is not
followed by medical interventions, patients have more hope
and expectations (allegiance or Hawthorne effect). Hope for
improvement is a crucial part for treatment response. The
choice of the control condition can affect the outcome of
an RCT because some control conditions, such as pill pla-
cebo, can produce effects comparable with active treat-
ments [48,49], while some others, such as WL, can
produce neutral or even negative effects, leading to larger
differences between interventions and controls [15,19].
WL seems to be ‘‘less effective’’ than NT. This may be ex-
plained from the design of studies: patients who are ran-
domized in NT or WL are free to seek other treatments
while they are monitored. However, patients on WL are
more likely to wait for the active treatment, whereas pa-
tients on NT have nothing to lose and may be more active
to seek for help elsewhere. WL may also increase a state of
helplessness during the waiting period, while increasing ex-
pectations for the upcoming intervention. It has been pro-
posed that different control conditions could be used in
different stages of RCTs [13,15]. The ‘‘weakest,’’ such as
WL, could be used at the initial phase when a new interven-
tion is introduced, and the ‘‘strongest,’’ such as pill placebo,
could be used at the final phase when the intervention is
considered for inclusion in treatment guidelines.5. Conclusions and policy implications
In summary, we found that different control conditions
produce different effect sizes in psychotherapy RCTs for
depression when they are all considered simultaneously in
NMA. All control conditions (PillPlacebo, NT, and Psy-
cholPlacebo) had higher ORs for response against WL.
The findings have clear implications first for the interpreta-
tions of RCTs of psychotherapies, second for the design of
such RCTs, and finally for the conduct of their meta-
analyses. First, the effect sizes obtained in RCTs must be
interpreted differently depending on the control condition
used. Second, one may use weaker controls only in the
earlier phases of therapy evaluations but must move to
stronger controls in confirmatory studies. And finally, in
meta-analyses and network meta-analyses of psychotherapy
trials, one should no longer lump various control conditions
into one comparison group.Acknowledgments
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